老年人血液中血管紧张素Ⅱ水平与认知功能及内侧颞叶萎缩的相关性研究

doi:10.3969/j.issn.1003-9198.2022.07.009

Abstract

Abstract: Objective To investigate the associations of angiotensin Ⅱ (AngⅡ) level with cognitive function and medial temporal atrophy (MTA) in the elderly. Methods Forty elderly patients with Alzheimer's disease (AD group) and 40 elderly with normal cognitive function (control group) were enrolled. All the subjects were evaluated by Chinese version of Addenbrooke's Cognitive Examination Ⅲ (ACE-Ⅲ), Mini-Mental State Examination (MMSE) and Activities of Daily Living Scale (ADL), and 24-hour blood pressure was measured. All the subjects were rated by medial temporal atrophy (MTA) scale on MRI. The level of AngⅡ was measured by enzyme-linked immunosorbent assay. Pearson correlation analysis was performed to evaluate the associations of AngⅡ level with cognitive function and MTA. Results The age, AngⅡ level, MTA score were significantly higher, and the scores of MMSE, ACE-Ⅲ and ADL were significantly lower in the AD group than those in the control group (P<0.05). There were no significant differences in the levels of systolic blood pressure and diastolic blood pressure between the two groups (P>0.05). The level of AngⅡ was not related to the scores of MMSE, ACE-Ⅲ and ADL (P<0.05), but positively correlated with MTA (r=0.228, P<0.05), and further study showed the correlation was not mediated by blood pressure. Conclusions The level of AngⅡ in the elderly patients with AD is higher than that in the normal elderly, and the increased level of AngⅡ is associated with MTA.

Key words: Alzheimer's disease, angiotensin Ⅱ, cognitive function, medial temporal atrophy

CLC Number:

R749.16

WANG Bian-rong, ZHENG Hui-fen, XU Chang, ZHANG He-di, HUANG Dan-qing, TIAN Qi, CHEN Chun-miao. Associations of angiotensin Ⅱ level with cognitive function and medial temporal atrophy in elderly[J]. Practical Geriatrics, 2022, 36(7): 684-687.

References

[1] YU J T, XU W, TAN C C, et al. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials[J]. J Neurol Neurosurg Psychiatry, 2020, 91(11):1201-1209.
[2] ITURRIA-MEDINA Y, SOTERO R C, TOUSSAINT D J, et al. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis[J]. Nat Commun, 2016, 7:11934.
[3] ASHBY E L, KEHOE P G. Current status of renin-aldosterone-angiotensin system targeting antihypertensive drugs as therapeutic options for Alzheimer's disease[J]. Exp Opin Investig Drugs, 2013, 22(10):1229-1242.
[4] SCOTTI L, BASSI L, SORANNA D, et al. Association between renin-angiotensin- aldosterone system inhibitors and risk of dementia: a meta-analysis[J]. Pharmacol Res, 2021, 166: 105515.
[5] INABA S, IWAI M, FURUNO M,et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice[J]. Am J Hypertens, 2009, 53(2):356-362.
[6] KEHOE P G, HIBBS E, PALMER L E,et al. Angiotensin-Ⅲ is increased in Alzheimer's disease in association with amyloid-β and tau pathology[J]. J Alzheimers Dis, 2017, 58(1):203-214.
[7] TAKEDA S, SATO N, OGIHARA T,et al. The renin-angiotensin system, hypertension and cognitive dysfunction in Alzheimer's disease: new therapeutic potential[J]. Front Biosci, 2008, 13:2253-2265.
[8] SCHELTENS P, LEYS D, BARKHOF F, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates[J]. J Neurol Neurosurg Psychiatry, 1992, 55(10):967-972.
[9] JOCHEMSEN H M, TEUNISSEN C E, ASHBY E L,et al. The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease[J]. Alzheimers Res Ther, 2014, 6(3):27.
[10] JOCHEMSEN H M, VAN DER FLIER W M, ASHBY E L,et al. Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy[J]. J Alzheimers Dis, 2015, 44(1):153-162.
[11] YASAR S, VARMA V R, HARRIS G C,et al. Associations of angiotensin converting enzyme-1 and angiotensin Ⅱ blood levels and cognitive function[J]. J Alzheimers Dis, 2018, 63(2):655-664.
[12] CLAUS J J, STAEKENBORG S S, HOLL D C,et al. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: validation in a large memory clinic population[J]. Eur Radiol, 2017, 27(8):3147-3155.
[13] VISSER P J, VERHEY F R, HOFMAN P A, et al. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment[J]. J Neurol Neurosurg Psychiatry, 2002 ,72(4):491-497.
[14] DUBOIS B, FELDMAN H H, JACOVA C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG -2 criteria[J]. Lancet Neurol, 2014, 13(8):614-629.
[15] YASAR S, MOORED K D, ADAM A, et al. Angiotensin II blood levels are associated with smaller hippocampal and cortical volumes in cognitively normal older adults[J]. J Alzheimers Dis, 2020, 75(2):521-529.

Associations of angiotensin Ⅱ level with cognitive function and medial temporal atrophy in elderly

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Metrics

Recommended 10

[1]	ZHENG Hong, QI Zhenbo, XU Peng, XU Jie, YU Xinyu, ZANG Yanan, ZHANG Zhaoyan. Effects of hypnotics on cognition function and daytime sleepiness in the elderly [J]. Practical Geriatrics, 2024, 38(9): 936-939.
[2]	GUO Chun, YI Mengting, ZONG Qianxing, ZHOU Yi, WU Haidi, MO Yongzhen. Development of a 6-month risk prediction model for hypoglycemia in elderly patients with type 2 diabetes mellitus: a longitudinal study [J]. Practical Geriatrics, 2024, 38(6): 592-597.
[3]	GUO Jinhua, SHEN Tiemei, CHEN Ling, CUI Hong, WANG Xiaoxia, HUANG Qiao, HUANG Fang, LI Yun, YANG Manqing. Prevalence and risk factors of cognitive function in elderly inrural areas of Guangdong Province [J]. Practical Geriatrics, 2024, 38(5): 456-437.
[4]	WANG Jinpeng, ZHANG Shun, ZHANG Xiaojuan, WANG Liping, MA Wenyou. Relationship of sleep spindles with depression, anxiety with cognitive function in elderly patients with first episode of depression [J]. Practical Geriatrics, 2024, 38(5): 505-437.
[5]	CHENG Qing, XU Yan, CHEN Guofei, DENG Xinyue. Correlation of serum angiotensin Ⅱ and nitric oxide levels with cognitive dysfunction in elderly patients with chronic heart failure [J]. Practical Geriatrics, 2024, 38(2): 132-135.
[6]	LI Meng-ting, ZHANG Liu-ping, XIE Qing-lei, WANG Yue, WANG Li-juan. A survey of prospective memory in elderly patients undergoing maintenance hemodialysis [J]. Practical Geriatrics, 2023, 37(8): 798-802.
[7]	REN Sha-sha, CHENG Kai, XU Liang, ZHOU Mo, GAO Ming-xia. Effects of transcranial direct current stimulation combined with motor imagery training on upper limb motor function and cognitive function in patients with hemiplegia after stroke [J]. Practical Geriatrics, 2023, 37(5): 449-453.
[8]	WU Gen-li, ZHANG Li, ZHAO Ya-xuan. Effects of social isolation, sleep quality and their interaction on cognitive function in the elderly [J]. Practical Geriatrics, 2023, 37(5): 495-499.
[9]	SUN Qiang, WU Bo, MAO Meng, WANG Fei, JI Mu-huo. Predictive value of subjective cognitive declineon postoperative delirium [J]. Practical Geriatrics, 2023, 37(2): 156-159.
[10]	LIU Hong, LI Yan-zhang, ZHANG Hui, XIONG Mei, ZHANG Yu-ping. Relationship between frailty and cognitive function of community-dwelling elderly: the mediating mechanism of resilience [J]. Practical Geriatrics, 2022, 36(8): 842-845.
[11]	ZHANG Chun-li, XU Zhi-xin, HUANG Yu-yuan, CHEN Ding-zhong. Effect of intraspinal anesthesia on postoperative cognitive function and NLRP3 inflammasome in elderly patients undergoing hip replacement [J]. Practical Geriatrics, 2022, 36(7): 720-724.
[12]	YU Pei-wen, BAO Hai-tong, CHEN Xing, TAN Ping, CHEN Shu, MAO Yan, TONG Qiang-wei. Oral nutrition supplementation in the elderly patients with cognitive frailty [J]. Practical Geriatrics, 2021, 35(12): 1265-1268.
[13]	FENG Cai-yun, YE Yong-xiu, XIONG Hai-yan. Investigation on cognitive function, depression and drug compliance in elderly patients with HIV [J]. Practical Geriatrics, 2021, 35(11): 1136-1139.